ZYNE (ZYNE) | |||
---|---|---|---|
1.3 0.03 (2.36%) | 10-10 16:00 | ||
Open: | 1.26 | Pre. Close: | 1.27 |
High: | 1.34 | Low: | 1.26 |
Volume: | 861,742 | Market Cap: | 70(M) |
Stock Technical Analysis | |
---|---|
Overall: | |
Target: | Six months: 1.57 -10000000000 One year: 1.83 -10000000000 |
Support: | Support1: 1.29 -10000000000 Support2: 1.26 -10000000000 |
Resistance: | Resistance1: 1.34 -10000000000 Resistance2: 1.57 -10000000000 |
Pivot: | -10000000000 |
Moving Averages: | MA(5): MA(20): MA(100): MA(250): |
MACD: | MACD(12,26): -10000000000.00 -10000000000 Signal(12,26,9): -10000000000.00 -10000000000 |
%K %D: | %K(14,3): -10000000000.00 -10000000000 %D(3): -10000000000.00 -10000000000 |
RSI: | RSI(14): -10000000000.00 -10000000000 |
52-Week: | High: 1.4 Low: 0.25 Change(%): |
Average Vol(K): | 3-Month: -10000000000 10-Days: -10000000000 |
Prices Prediction (Update @5:00pm) | ||
---|---|---|
If tomorrow: | Open lower | Open higher |
High: | - | - |
Low: | - | - |
Close: | - | - |
Price, MAs and Bollinger Bands |
---|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZYNE ] has closed Bollinger Bands are 0% narrower than normal. |
Company profile |
---|
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. |
Stock chart |
---|
Financial Analysis | |
---|---|
Price to Book Value: | Underperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
Price to Earnings: | Neutral |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
Discounted cash flow: | Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
Return on Assets: | Underperform |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
Return on Equity: | Underperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
Debt to Equity: | Underperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Stock Basics & Statistics | |
---|---|
Exchange: NASDAQ Global Market | |
Sector: Healthcare | |
Industry: Drug Manufacturers - Specialty & Generic | |
Shares Out. (M) | |
Shares Float (M) | |
% Held by Insiders | |
% Held by Institutions | |
Shares Short (K) | |
Shares Short Prior Month (K) |
Stock Financials | |
---|---|
EPS | |
Book Value (p.s.) | |
Profit Margin | |
Operating Margin | |
Return on Assets (ttm) | |
Return on Equity (ttm) | |
Qtrly Rev. Growth | |
Gross Profit (p.s.) | |
Sales Per Share | |
EBITDA (p.s.) | |
Qtrly Earnings Growth | |
Operating Cash Flow (M) | |
Levered Free Cash Flow (M) |
Stock Valuation | |
---|---|
PE Ratio | |
PEG Ratio | |
Price to Book value | |
Price to Sales | |
Price to Cash Flow |
Stock Dividends | |
---|---|
Dividend | |
Dividend Yield | |
Dividend Growth |